Visit-to-visit variability of the systolic BP or diastolic BP during the follow-up period in patients receiving ARB plus CCB therapy or high-dose ARB therapy in the above-mentioned four CVD-eGFR ...

The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was a comparative study of the angiotensin II receptor blocker (ARB), candesartan, and a calcium channel blocker (CCB ...

an angiotensin receptor blocker (ARB), and amlodipine, a calcium-channel blocker (CCB) (Exforge HCT, Novartis). The approval isn't for first-line hypertensive therapy. Instead, the drug is ...